Analysts’ Top Healthcare Picks: XLRN, AGIO

By Austin Angelo

Analysts fell to the sidelines weighing in on Acceleron Pharma (NASDAQ: XLRN) and Agios Pharma (NASDAQ: AGIO) with neutral ratings,indicating that the experts are neither bullish nor bearish on the stocks.

Acceleron Pharma (NASDAQ: XLRN)

Oppenheimer analyst Leah R. Cann reiterated a Hold rating on Acceleron Pharma (NASDAQ: XLRN) today. The company’s shares closed last Friday at $34.10.

R. Cann said:

“Acceleron Pharma and Celgene Corporation announced on Friday, June 23rd preliminary results from the ongoing phase II studies of Luspatercept in patients with lower-risk myelodysplastic syndromes (MDS) at the European Hematology Association (EHA) meeting in Madrid, Spain. These data presented Friday appear to be slightly better than data presented in May.”

According to TipRanks.com, Cann is a 4-star analyst with an average return of 12.5% and a 84.3% success rate. Cann covers the Healthcare sector, focusing on stocks such as CytomX Therapeutics Inc, Syros Pharmaceuticals, and Seattle Genetics.

Acceleron Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $39.83.

Agios Pharma (NASDAQ: AGIO)

Janney Montgomery analyst Debjit Chattopadhyay downgraded Agios Pharma (NASDAQ: AGIO) to Hold today. The company’s shares closed last Friday at $59.18.

According to TipRanks.com, Chattopadhyay is a 1-star analyst with an average return of -0.2% and a 46.4% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Strongbridge Biopharma Plc, and Ionis Pharmaceuticals Inc.

Agios Pharma has an analyst consensus of Strong Buy, with a price target consensus of $77.67.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.